Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company... Show more
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SCNX declined for three days, in of 352 cases, the price declined further within the following month. The odds of a continued downward trend are .
The Aroon Indicator for SCNX entered a downward trend on February 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SCNX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.028) is normal, around the industry mean (3.463). P/E Ratio (0.000) is within average values for comparable stocks, (181.246). SCNX's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.915). Dividend Yield (0.000) settles around the average of (0.050) among similar stocks. SCNX's P/S Ratio (1.977) is slightly higher than the industry average of (0.903).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
a provider of an online platform for pharmaceutical purchasers
Industry DrugstoreChains
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
GEACX | 17.20 | 0.20 | +1.18% |
GMO Resources I | |||
CSXRX | 49.50 | 0.25 | +0.51% |
Calvert US Large Cap Core Rspnb Idx R6 | |||
BDAIX | 27.50 | 0.06 | +0.22% |
Baron Durable Advantage Institutional | |||
SGHIX | 11.01 | 0.02 | +0.18% |
Sextant Global High Income | |||
VSFIX | 23.21 | 0.03 | +0.13% |
Federated Hermes Clover Small Value IS |
A.I.dvisor tells us that SCNX and LFMD have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCNX and LFMD's prices will move in lockstep.
Ticker / NAME | Correlation To SCNX | 1D Price Change % | ||
---|---|---|---|---|
SCNX | 100% | -34.44% | ||
LFMD - SCNX | 22% Poorly correlated | -3.31% | ||
SSY - SCNX | 4% Poorly correlated | -3.52% | ||
YI - SCNX | 4% Poorly correlated | -0.57% | ||
PETS - SCNX | 3% Poorly correlated | +0.48% | ||
WBA - SCNX | 1% Poorly correlated | +7.45% | ||
More |